Astrazeneca Ab

Paul David Kemmitt

Alan Martin Birch

Jason Grant Kettle

Frederick Woolf Goldberg

Andrew John Eatherton

Graeme Richard Robb

Shaun Michael Fillery

Scott Gibson Lamont

The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Tetracyclic heteroaryl compounds

Compounds of formula (I) or salts thereof, wherein A, and Rto Rare as defined in the specification, are DGAT-1 inhibitors and are thereby useful in the treatment of, for example, obesity. Processes to make compounds of formula (I) are also described. 

Pyrimido [4,5-B]-oxazines for use as DGAT inhibitors

Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors

Growing community of inventors

Macclesfield, United Kingdom

Paul David Kemmitt